Technology Networks: Addressing Key Limitations in Disease Models

At the European Laboratory Research and Innovation Group’s (ELRIG) Drug Discovery 2024 event, our CTO Chris Saunter was asked how Magnitude Bioscience's technology addresses key limitations in traditional disease models, along with a selection of start-up companies featured in the conference’s Breakthrough Zone.

“Traditional cell models struggle with two key challenges: translatability and the inability to model aging. Cells – except for certain types like fibroblasts – don’t naturally age, limiting their usefulness in studying age-related diseases. Mammalian models, while more predictive, are costly and can take months or years to generate the same data.”

“Our [Magnitude Biosciences] Caenorhabditis elegans (C. elegans) platform addresses both of these limitations. The worms have a lifecycle of just three days, and have a total lifespan of two-three weeks, allowing us to rapidly test compounds for their effects on aging and longevity. This offers a significant advantage over traditional models, both in terms of cost and speed. We believe that our scalable, whole-organism approach will play a pivotal role in the future of disease modeling, particularly in aging research, where there’s a growing need for faster and more predictive models.”

Read the full article: https://www.technologynetworks.com/tn/blog/biotech-start-ups-share-how-they-are-addressing-key-limitations-in-disease-models-392269